Recent Quotes
My Watchlist
Indicators
Local Stocks
San Gabriel Valley
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

GeoVax Labs, Inc. - Common Stock (NQ: GOVX )

1.670 +0.040 (+2.45%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 21, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about GeoVax Labs, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
14 15 Next >
Mpox Clade 1 in the U.S. Highlights the Need for Vaccine Supply Diversification
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Economy Supply Chain
Exposures Supply Chain
Mpox Clade 1 in the U.S. Highlights the Need for Vaccine Supply Diversification
GeoVax Advances GEO-MVA to Strengthen U.S. and Global Readiness 
Via TheNewswire.com
Topics Economy Supply Chain
Exposures Supply Chain
GeoVax Pledges Continued Support for Vaccine Innovation, Transparency, and Public Health
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
GeoVax Pledges Continued Support for Vaccine Innovation, Transparency, and Public Health
GeoVax’s Vaccine Development Programs Align with Anticipated HHS Focus on Vaccine Safety, Diversification and Domestic Biosecurity 
Via TheNewswire.com
GeoVax to Present at the Emerging Growth Conference on February 19, 2025
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Strengthening America's Biosecurity: GeoVax Advances Domestic Vaccine Capability
Addressing Critical U.S. Vulnerabilities in Vaccine Supply and National Preparedness 
Via TheNewswire.com
Topics Supply Chain
Exposures Supply Chain
GeoVax Announces Major Gedeptin Milestone With Plans of Phase 2 Trial
Represents a Key Step Toward Validating Gedeptin Potential in Solid Tumor Therapy 
Via TheNewswire.com
Exposures Product Safety
Earnings Scheduled For November 12, 2024
Via Benzinga
GeoVax to Present at the Emerging Growth Conference on February 19, 2025
Company to Provide an Update on Its Mpox Vaccine Program 
Via TheNewswire.com
GeoVax Congratulates Dr. Valerie Montgomery Rice on Receiving the 2025 Healthcare Champions Lifetime Achievement Award
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
GeoVax Congratulates Dr. Valerie Montgomery Rice on Receiving the 2025 Healthcare Champions Lifetime Achievement Award
Recognizing a Visionary Leader in Advancing Healthcare Access for Minority and Vulnerable Populations Worldwide 
Via TheNewswire.com
GeoVax Anticipates Significant 2025 Progress With Catalyst-Rich Milestones Across Key Programs
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Artificial Intelligence
Exposures Artificial Intelligence COVID-19
GeoVax Anticipates Significant 2025 Progress With Catalyst-Rich Milestones Across Key Programs
Strategic Progress Across COVID-19, Mpox, Oncology Therapies and AI Integration Positions GeoVax for Strong Momentum 
Via TheNewswire.com
Topics Artificial Intelligence
Exposures Artificial Intelligence COVID-19
GeoVax to Showcase Advancements in Vaccines & Immunotherapies at the 2025 BIO CEO & Investor Conference
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Exposures COVID-19
GeoVax to Showcase Advancements in Vaccines &amp; Immunotherapies at the 2025 BIO CEO &amp; Investor Conference
ATLANTA, GA - February 4, 2025 (NEWMEDIAWIRE) - GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, announced... 
Via TheNewswire.com
Exposures COVID-19
GeoVax Announces Strategic Integration of AI in Support of President Trump's Stargate Initiative
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Artificial Intelligence Government
Exposures Artificial Intelligence Political
GeoVax Announces Strategic Integration of AI in Support of President Trump's Stargate Initiative
Harnessing AI to Revolutionize Vaccine and Therapy Development 
Via TheNewswire.com
Topics Artificial Intelligence Government
Exposures Artificial Intelligence Political
Strengthening America's Biosecurity: GeoVax Advances Domestic Vaccine Capability
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Supply Chain
Exposures Supply Chain
GeoVax Advanced MVA Manufacturing Process: Aimed to Enhance Vaccine Supply Worldwide
Process Expected to Increase Production Yield, Flexibility at Lower Cost 
Via TheNewswire.com
GeoVax Advanced MVA Manufacturing Process: Aimed to Enhance Vaccine Supply Worldwide
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
GeoVax Announces Major Gedeptin Milestone With Plans of Phase 2 Trial
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Exposures Product Safety
GeoVax Achieves Significant Progress in Next-Generation COVID-19 Vaccine Development Throughout 2024
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Exposures COVID-19
GeoVax Achieves Significant Progress in Next-Generation COVID-19 Vaccine Development Throughout 2024
Advancements Position GEO-CM04S1 as a Leading Vaccine Candidate Addressing Unmet Medical Needs, Especially Among Immunocompromised Patients 
Via TheNewswire.com
Exposures COVID-19
GeoVax to Review 2024 Progress at the Emerging Growth Conference on January 16, 2025
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Exposures COVID-19
GeoVax to Review 2024 Progress at the Emerging Growth Conference on January 16, 2025
Company to provide updates on progress toward the BARDA-funded Phase 2b trial of GEO-CM04S1, its next-generation COVID-19 vaccine as well as for Gedeptin® (solid tumor therapy) and GEO-MVA... 
Via TheNewswire.com
Exposures COVID-19
GeoVax to Review 2024 Progress at Biotech Showcase During J.P. Morgan Healthcare Week 2025
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
GeoVax to Review 2024 Progress at Biotech Showcase During J.P. Morgan Healthcare Week 2025
ATLANTA, GA - January 6, 2025 (NEWMEDIAWIRE) - GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced... 
Via TheNewswire.com
3 Penny Stocks Ready to Break Out in 2025
Vuzix, GeoVox Labs, and Cardiol Therapeutics emerged as notable penny stocks late in 2024 for their potential to scale operations and launch new products. 
Via MarketBeat
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
This GeoVax Labs Analyst Begins Coverage On A Bullish Note; Here Are Top Initiations For Monday
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
14 15 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.